Published in Liver Int on February 07, 2008
Prevalence of hepatitis B & hepatitis C virus infections in potential blood donors in rural Vietnam. Indian J Med Res (2012) 1.28
Hepatitis B immunization strategies: timing is everything. CMAJ (2009) 1.18
A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One (2012) 1.07
Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One (2011) 1.02
Chronic hepatitis B in Asian women of childbearing age. Hepatol Int (2009) 0.95
Risk factors for hepatitis B infection in rural Vietnam. Asian Pac J Cancer Prev (2009) 0.95
A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination. Vaccine (2013) 0.95
High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam. PLoS One (2013) 0.90
Estimation of Cancer Burden Attributable to Infection in Asia. J Epidemiol (2015) 0.89
Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC Public Health (2015) 0.87
Cancer incidence among Asian American populations in the United States, 2009-2011. Int J Cancer (2016) 0.86
Association of CISH -292A/T genetic variant with hepatitis B virus infection. Immunogenetics (2011) 0.83
Economic burden of hepatitis B virus-related diseases: evidence from iran. Hepat Mon (2015) 0.81
Dangerous practices in a hemodialysis unit in Vietnam identify from mixed methods. BMC Infect Dis (2017) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Authors' response. Indian J Med Res (2013) 0.75
Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment. BMC Infect Dis (2015) 0.75
Interferon-stimulated gene 15 in hepatitis B-related liver diseases. Oncotarget (2016) 0.75
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol (2003) 2.65
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis (2009) 2.24
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med (2015) 2.14
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis (2011) 2.08
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS (2002) 1.98
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol (2003) 1.78
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology (2010) 1.77
Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol (2004) 1.77
Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men. Sex Health (2009) 1.70
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS (2004) 1.62
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol (2009) 1.61
Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis (2013) 1.61
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS (2014) 1.59
Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol (2004) 1.55
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS (2006) 1.52
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS (2007) 1.49
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS (2003) 1.47
Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol (2006) 1.45
Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase. Med J Aust (2003) 1.41
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis (2013) 1.38
Highly endemic hepatitis B infection in rural Vietnam. J Gastroenterol Hepatol (2007) 1.38
Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis (2005) 1.36
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol (2007) 1.35
Suicide risk among recently released prisoners in New South Wales, Australia. Med J Aust (2007) 1.28
Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol (2010) 1.26
Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis (2013) 1.23
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
What is killing people with hepatitis C virus infection? Semin Liver Dis (2011) 1.21
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health (2010) 1.18
Factors associated with mortality in a cohort of Australian prisoners. Eur J Epidemiol (2007) 1.18
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS (2009) 1.17
Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr (2009) 1.16
Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health (2004) 1.15
Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther (2005) 1.14
Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One (2012) 1.14
Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis (2013) 1.14
Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology (2008) 1.13
Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS (2012) 1.11
Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. AIDS (2007) 1.11
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol (2010) 1.10
Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog (2008) 1.10
Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels? Hepatology (2014) 1.09
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis (2013) 1.09
Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis (2005) 1.09
Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology (2009) 1.09
Hepatitis C Virus Treatment and Persons Who Inject Drugs. Ann Intern Med (2016) 1.08
Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol (2005) 1.08
Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS (2011) 1.08
Risk factors and causes of death in the Australian HIV Observational Database. Sex Health (2006) 1.07
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology (2012) 1.07
Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend (2006) 1.05
Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis (2004) 1.04
The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr (2009) 1.04
HIV and hepatitis C coinfection. J Gastroenterol Hepatol (2008) 1.04
Blood-borne viruses and their survival in the environment: is public concern about community needlestick exposures justified? Aust N Z J Public Health (2003) 1.04
Late HIV presentation among AIDS cases in Australia, 1992-2001. Aust N Z J Public Health (2003) 1.03
Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev (2012) 1.03
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc (2012) 1.03
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology (2009) 1.03
Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol (2011) 1.02
HCV reinfection studies and the door to vaccine development. J Hepatol (2009) 1.02
Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol (2014) 1.02
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int (2013) 1.01
Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol (2012) 1.01
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther (2007) 1.00
Modeling trends in HIV incidence among homosexual men in Australia 1995-2006. J Acquir Immune Defic Syndr (2004) 1.00
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99